How to Help Your Patients Save Money on Farxiga: A Provider's Guide to Savings Programs

Medication cost is one of the most common reasons patients with type 2 diabetes, heart failure, and chronic kidney disease don't take their Farxiga (dapagliflozin) as prescribed. At $590–$778 per month at retail, the financial burden is real — and when patients can't afford their medication, the clinical outcomes you worked to achieve don't materialize. This guide equips you with every tool available in 2026 to help your patients afford Farxiga.

Why Cost Matters for Farxiga Adherence

The clinical evidence for Farxiga's benefit in heart failure and CKD is unambiguous. DAPA-HF demonstrated a 26% relative reduction in the composite of CV death, worsening HF, or urgent HF visits. DAPA-CKD showed a 39% reduction in the risk of eGFR decline ≥50%, ESKD, or renal/CV death. But these benefits require consistent, long-term use. Cost-related non-adherence — patients skipping doses, splitting pills, or simply not filling their prescription — erases these gains entirely.

As a prescriber, knowing the cost landscape and having savings resources at your fingertips is a direct clinical intervention.

The April 2026 Generic Dapagliflozin Launch: What It Means Clinically and Financially

On April 7, 2026, the FDA approved the first generics of dapagliflozin from multiple manufacturers simultaneously. Clinically, FDA-approved generics are bioequivalent and therapeutically equivalent to brand-name Farxiga — same prescribing information, same indications, same warnings.

Practically, this means:

Prescribing generically (without 'dispense as written') allows pharmacy substitution to the generic, which insurance plans may cover at a lower tier

Insurance plans will begin updating formularies to place generic dapagliflozin at lower tiers, potentially reducing patient copays significantly

In the early transition period, brand Farxiga with manufacturer savings card may still be cheaper for some patients — counsel patients to compare at their specific pharmacy

PA requirements: some plans may now require generic dapagliflozin (step therapy) before approving brand Farxiga

Savings Resource 1: The Farxiga SavingsRx Card (Commercial Insurance)

For your commercially insured patients, the Farxiga SavingsRx Card from AstraZeneca is the most powerful cost-reduction tool available:

Commercially insured: Pay as little as $0 per 30-day supply; maximum savings of $175 per fill

Uninsured (cash): AstraZeneca pays the first $150 of the retail price per monthly prescription

Applies to: Brand-name Farxiga only (not generic dapagliflozin)

Excludes: Patients with Medicare, Medicaid, or other government-funded programs

Enrollment: farxiga.com/savings-support or 1-855-332-7944

Clinical recommendation: Add SavingsRx Card enrollment to your standard Farxiga prescribing workflow for all commercially insured patients. Your medical assistant or patient navigator can complete this at the point of care.

Savings Resource 2: AstraZeneca Patient Assistance Program

For uninsured or underinsured patients who cannot afford Farxiga even with the SavingsRx Card, AstraZeneca's Patient Assistance Program (PAP) provides medication at no or low cost based on income. The program is income-based and requires application, but can be a lifeline for patients with limited means.

Process: Patients contact AstraZeneca's dedicated support line at 1-855-332-7944 or visit azpatientsupport.com. Your practice may be asked to submit documentation confirming the diagnosis. Most practices designate a care coordinator or social worker to assist with PAP applications.

Savings Resource 3: Navigating Medicare Coverage

Medicare patients are among the most common Farxiga users (given age-related HF and CKD prevalence), but they cannot use the manufacturer's savings card. Key Medicare considerations in 2026:

Farxiga is covered by most Medicare Part D plans, but the tier and copay vary. Advise patients to check their specific plan's formulary.

Farxiga was selected for Medicare drug price negotiation in 2024 (first negotiation cycle). The negotiated prices apply to Medicare Part D plans beginning in 2026 — patients should confirm their plan's current pricing.

Extra Help/Low Income Subsidy (LIS): For eligible low-income Medicare patients, this federally funded program reduces Part D drug costs significantly. Refer eligible patients to ssa.gov/extrahelp or 1-800-MEDICARE.

Annual out-of-pocket cap: As of 2026, Medicare Part D has a $2,100 annual out-of-pocket maximum. Once reached, the plan covers full cost for the rest of the year.

Savings Resource 4: GoodRx and Discount Platforms

For patients who don't qualify for the savings card or PAP, GoodRx can reduce the cash price of Farxiga to approximately $288 per 30-day supply at many pharmacies — roughly 51% off retail. Note that GoodRx cannot be combined with Medicare.

SingleCare and RxSaver are alternative discount platforms that may offer different pricing at different pharmacies. Counsel patients to check multiple platforms.

Prior Authorization Tips to Reduce Access Delays

Insurance access delays — especially PA requirements — are as significant a cost barrier as price, because patients who run out while waiting for approval often stop taking the medication. Proactive PA strategies:

Submit PA at time of prescribing, not after the first rejection

Include relevant labs (eGFR, UACR, HbA1c, LVEF) in the PA submission upfront

For step therapy overrides: document specific clinical reasons for Farxiga over required first-line alternatives

Provide drug samples to bridge the gap while PA is pending for high-risk HF or CKD patients

Helping Patients Who Can't Find Farxiga at Their Pharmacy

Even after cost is resolved, some patients can't find Farxiga physically in stock at their local pharmacy. Refer these patients to medfinder.com — the service calls pharmacies in the patient's area to find which ones have the medication available, saving patients hours of frustration and reducing the likelihood of treatment gaps.

Quick Reference: Savings Resources by Patient Type

Commercially insured: Farxiga SavingsRx Card — as low as $0/month (farxiga.com or 1-855-332-7944)

Uninsured / underinsured: AstraZeneca PAP (azpatientsupport.com) + GoodRx ($288/month)

Medicare patients: Confirm Part D formulary tier; refer to Extra Help/LIS if low income (ssa.gov/extrahelp)

All patients: Ask about generic dapagliflozin (FDA-approved April 2026) — may be covered at lower tier than brand

For guidance on helping patients who can't find Farxiga in stock (separate from cost issues), see our complementary guide: how to help your patients find Farxiga in stock: a provider's guide.